These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 34653252

  • 1. Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia.
    Auchus RJ, Sarafoglou K, Fechner PY, Vogiatzi MG, Imel EA, Davis SM, Giri N, Sturgeon J, Roberts E, Chan JL, Farber RH.
    J Clin Endocrinol Metab; 2022 Feb 17; 107(3):801-812. PubMed ID: 34653252
    [Abstract] [Full Text] [Related]

  • 2. Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia.
    Newfield RS, Sarafoglou K, Fechner PY, Nokoff NJ, Auchus RJ, Vogiatzi MG, Jeha GS, Giri N, Roberts E, Sturgeon J, Chan JL, Farber RH.
    J Clin Endocrinol Metab; 2023 Oct 18; 108(11):2871-2878. PubMed ID: 37216921
    [Abstract] [Full Text] [Related]

  • 3. Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency.
    Turcu AF, Spencer-Segal JL, Farber RH, Luo R, Grigoriadis DE, Ramm CA, Madrigal D, Muth T, O'Brien CF, Auchus RJ.
    J Clin Endocrinol Metab; 2016 Mar 18; 101(3):1174-80. PubMed ID: 26751191
    [Abstract] [Full Text] [Related]

  • 4. Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies.
    Sarafoglou K, Barnes CN, Huang M, Imel EA, Madu IJ, Merke DP, Moriarty D, Nakhle S, Newfield RS, Vogiatzi MG, Auchus RJ.
    J Clin Endocrinol Metab; 2021 Oct 21; 106(11):e4666-e4679. PubMed ID: 34146101
    [Abstract] [Full Text] [Related]

  • 5. Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency.
    Auchus RJ, Buschur EO, Chang AY, Hammer GD, Ramm C, Madrigal D, Wang G, Gonzalez M, Xu XS, Smit JW, Jiao J, Yu MK.
    J Clin Endocrinol Metab; 2014 Aug 21; 99(8):2763-70. PubMed ID: 24780050
    [Abstract] [Full Text] [Related]

  • 6. Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.
    Auchus RJ, Hamidi O, Pivonello R, Bancos I, Russo G, Witchel SF, Isidori AM, Rodien P, Srirangalingam U, Kiefer FW, Falhammar H, Merke DP, Reisch N, Sarafoglou K, Cutler GB, Sturgeon J, Roberts E, Lin VH, Chan JL, Farber RH, CAHtalyst Adult Trial Investigators.
    N Engl J Med; 2024 Jun 01. PubMed ID: 38828955
    [Abstract] [Full Text] [Related]

  • 7. Relationships of basal level of serum 17-hydroxyprogesterone with that of serum androstenedione and their stimulated responses to a low dose of ACTH in young adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Kang MJ, Kim SM, Lee YA, Shin CH, Yang SW.
    J Korean Med Sci; 2011 Nov 01; 26(11):1454-60. PubMed ID: 22065901
    [Abstract] [Full Text] [Related]

  • 8. A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.
    El-Maouche D, Merke DP, Vogiatzi MG, Chang AY, Turcu AF, Joyal EG, Lin VH, Weintraub L, Plaunt MR, Mohideen P, Auchus RJ.
    J Clin Endocrinol Metab; 2020 Aug 01; 105(8):2771-8. PubMed ID: 32589738
    [Abstract] [Full Text] [Related]

  • 9. 3 alpha-androstanediol glucuronide in virilizing congenital adrenal hyperplasia: a useful serum metabolic marker of integrated adrenal androgen secretion.
    Pang S, MacGillivray M, Wang M, Jeffries S, Clark A, Rosenthal I, Wiegensberg M, Riddick L.
    J Clin Endocrinol Metab; 1991 Jul 01; 73(1):166-74. PubMed ID: 2045467
    [Abstract] [Full Text] [Related]

  • 10. Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia.
    Sarafoglou K, Kim MS, Lodish M, Felner EI, Martinerie L, Nokoff NJ, Clemente M, Fechner PY, Vogiatzi MG, Speiser PW, Auchus RJ, Rosales GBG, Roberts E, Jeha GS, Farber RH, Chan JL, CAHtalyst Pediatric Trial Investigators.
    N Engl J Med; 2024 Jun 02. PubMed ID: 38828945
    [Abstract] [Full Text] [Related]

  • 11. Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia.
    Ng SM, Stepien KM, Krishan A.
    Cochrane Database Syst Rev; 2020 Mar 19; 3(3):CD012517. PubMed ID: 32190901
    [Abstract] [Full Text] [Related]

  • 12. Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers.
    Debono M, Mallappa A, Gounden V, Nella AA, Harrison RF, Crutchfield CA, Backlund PS, Soldin SJ, Ross RJ, Merke DP.
    Eur J Endocrinol; 2015 Dec 19; 173(6):727-37. PubMed ID: 26340969
    [Abstract] [Full Text] [Related]

  • 13. Steroid 17-Hydroxyprogesterone in Hair Is a Potential Long-Term Biomarker of Androgen Control in Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.
    Auer MK, Krumbholz A, Bidlingmaier M, Thieme D, Reisch N.
    Neuroendocrinology; 2020 Dec 19; 110(11-12):938-949. PubMed ID: 31711056
    [Abstract] [Full Text] [Related]

  • 14. Serum 21-Deoxycortisol, 17-Hydroxyprogesterone, and 11-deoxycortisol in classic congenital adrenal hyperplasia: clinical and hormonal correlations and identification of patients with 11beta-hydroxylase deficiency among a large group with alleged 21-hydroxylase deficiency.
    Tonetto-Fernandes V, Lemos-Marini SH, Kuperman H, Ribeiro-Neto LM, Verreschi IT, Kater CE.
    J Clin Endocrinol Metab; 2006 Jun 19; 91(6):2179-84. PubMed ID: 16551734
    [Abstract] [Full Text] [Related]

  • 15. Pituitary-adrenal responses to corticotropin-releasing factor in late onset 21-hydroxylase deficiency.
    Carmina E, Lobo RA.
    Fertil Steril; 1990 Jul 19; 54(1):79-83. PubMed ID: 2162789
    [Abstract] [Full Text] [Related]

  • 16. Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia.
    Çakir ED, Mutlu FS, Eren E, Paşa AO, Sağlam H, Tarim O.
    J Clin Res Pediatr Endocrinol; 2012 Jun 19; 4(2):94-100. PubMed ID: 22672867
    [Abstract] [Full Text] [Related]

  • 17. Results of the ACTH stimulation test in hirsute women.
    Erel CT, Senturk LM, Oral E, Mutlu H, Colgar U, Seyisoglu H, Ertungealp E.
    J Reprod Med; 1999 Mar 19; 44(3):247-52. PubMed ID: 10202742
    [Abstract] [Full Text] [Related]

  • 18. Inappropriate adrenal androgen secretion with once-a-day corticosteroid therapy for congenital adrenal hyperplasia.
    Keenan BS, Eberle AE, Lin TH, Clayton GW.
    J Pediatr; 1990 Jan 19; 116(1):133-6. PubMed ID: 2153199
    [Abstract] [Full Text] [Related]

  • 19. Congenital Adrenal Hyperplasia: Time to Replace 17OHP with 21-Deoxycortisol.
    Miller WL.
    Horm Res Paediatr; 2019 Jan 19; 91(6):416-420. PubMed ID: 31450227
    [Abstract] [Full Text] [Related]

  • 20. Isolated precocious pubarche: an approach.
    Balducci R, Boscherini B, Mangiantini A, Morellini M, Toscano V.
    J Clin Endocrinol Metab; 1994 Aug 19; 79(2):582-9. PubMed ID: 8045980
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.